ImmunityBio Inc
ImmunityBio Inc (IBRX) Implied Volatility Current
IBRX's 30 day implied volatility is 117.52%, with an IV Rank of 58.73%. This is an average IV Rank versus the past year, meaning ImmunityBio Inc options are fairly priced and currently offer no clear edge to buyers or sellers. IBRX's 30 day historical volatility sits at 101.11%, which means implied volatility is running 16.41 points above historical volatility, as of Nov 20, 2026.
Read more
Tracking IBRX implied volatility helps you spot when ImmunityBio Inc options are historically cheap or expensive, and where the best trades are hiding. When IBRX IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor IBRX implied volatility current levels in real time and filter for high probability trades.
Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking IBRX IV rank helps you see whether IBRX's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co.
Implied Volatility
IV is slightly elevated. Premiums are richer, leaning toward sellers.
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →